Hereditary Angioedema — CPB 0782 | AETNA Coverage Update

Aetna modified CPB 0782 for hereditary angioedema (HAE), effective November 15, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0782 governing HAE coverage across commercial plans. This revision adds new prophylactic agents—including donidalorsen (Dawnzera)—and tightens the medical necessity criteria for existing drugs like Cinryze (J0598), lanadelumab-flyo (J0593), and ecallantide (J1290). If your practice or specialty pharmacy bills any HAE prophylaxis or acute treatment agent, review your prior authorization workflows before the November 15, 2025 effective date.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Hereditary Angioedema — CPB 0782
Policy Code	CPB 0782
Change Type	Modified
Effective Date	November 15, 2025
Impact Level	High
Specialties Affected	Allergy/Immunology, Hematology, Specialty Pharmacy, Infusion Therapy
Key Action	Update prior authorization templates and charge capture for all HAE prophylaxis agents before November 15, 2025

---

Aetna Hereditary Angioedema Coverage Criteria and Medical Necessity Requirements 2025

The Aetna hereditary angioedema coverage policy under CPB 0782 applies to all commercial medical plan members. Medicare members fall under separate criteria—check Aetna's Medicare Part B Step Therapy guidelines instead.

Precertification is required for all HAE agents. Call (866) 752-7021 or fax (888) 267-3277. Don't wait until a claim denies to find out a drug needed prior authorization—this is a precertification-first policy.

Cinryze (J0598) — Initial Approval Criteria

Aetna covers human C1 esterase inhibitor (Cinryze, billed as J0598) for HAE prophylaxis when all of these conditions are met:

The lab documentation piece matters here. C1-INH antigenic level below the lab's lower limit of normal satisfies the deficiency prong. A normal antigenic level with a functional C1-INH below 50% also satisfies it. Make sure the clinical records include the actual lab values, not just a narrative statement of deficiency. Claim denials on Cinryze often trace back to missing quantitative lab documentation.

Cinryze (J0598) — Continuation Criteria

Continuation approval requires four conditions, all of which must be met:

The ≥50% attack frequency reduction is an objective threshold. Document this in the chart before submitting the continuation request. Qualitative language like "patient is doing better" won't clear the bar.

Dawnzera (Donidalorsen) — Initial Approval

Aetna added donidalorsen (Dawnzera) to CPB 0782 as a covered prophylactic agent for HAE. This is one of the meaningful additions in the November 2025 update. The medical necessity criteria mirror the Cinryze framework: HAE specialist prescribing or consultation, no combination use with other HAE prophylaxis agents, and the same C1-INH deficiency/dysfunction or genetic variant/family history pathway.

Watch for the combination use restriction across all prophylactic agents. Aetna won't cover two prophylaxis drugs simultaneously under this coverage policy. If a member is transitioning between agents, document the transition clearly and ensure only one drug is active at the time of the prior auth submission.

Lanadelumab (Takhzyro, J0593)

Lanadelumab-flyo (J0593) is listed under HCPCS codes covered for indications in CPB 0782. It follows the same HAE specialist and C1-INH documentation pathway. Hereditary angioedema billing for J0593 requires the same lab confirmation and specialist consultation documentation as Cinryze.

Acute Treatment Agents

Aetna covers Ruconest (recombinant C1 esterase inhibitor, J0596), Berinert (human C1 esterase inhibitor, J0597), and ecallantide (J1290) when selection criteria are met. These are acute attack agents, not prophylactic. Don't bill them under the prophylaxis criteria pathway—they have separate coverage requirements.

Infusion administration codes—CPT 96365, 96366, 96367, 96368 for IV infusions and 96374, 96375, 96376 for IV push—apply to the intravenous agents. Subcutaneous administration uses 96372. Get the administration code right based on the actual route of delivery or you'll create a mismatch that triggers a claim denial.

Site of Care — Cinryze Specifically

Aetna's Site of Care Utilization Management Policy applies to Cinryze. This is a separate policy layer on top of CPB 0782. If your billing team handles Cinryze infusions across multiple settings—home infusion, outpatient infusion center, or physician office—confirm the site-of-service requirements before billing. Cinryze billed at the wrong site of care will deny even if the medical necessity criteria are fully met. Reimbursement depends on getting both the clinical and site criteria right.

---

Aetna Hereditary Angioedema Exclusions and Non-Covered Indications

Aetna considers all other uses of Cinryze—outside the HAE prophylaxis criteria listed above—to be experimental, investigational, or unproven. The policy is explicit on this.

The combination-use restriction is functionally an exclusion. If a member is on two HAE prophylaxis agents simultaneously, neither will qualify for coverage under this policy. This is a real prior auth trap. If a specialist is layering agents during a transition, get that transition timeline documented and communicate it to your authorization team.

Angioedema caused by ACE inhibitors, estrogen-containing drugs, or allergic mechanisms is explicitly excluded from these coverage criteria. Document the differential diagnosis workup in the medical record before submitting.

---

Coverage Indications at a Glance

---

Aetna Hereditary Angioedema Billing Guidelines and Action Items 2025

Copy Action Items

If your practice sees high HAE volume or manages complex payer mixes, loop in your compliance officer before the November 15 effective date. The combination-use restriction and site-of-care requirements create overlapping policy layers that can produce unexpected denials.

---

CPT, HCPCS, and ICD-10 Codes for Hereditary Angioedema Under CPB 0782

HCPCS Codes — HAE Agents

CPT Codes — Administration and Diagnostic

Key ICD-10-CM Diagnosis Codes

D84.1 is your primary diagnosis anchor for C1-INH deficiency HAE. T78.3XXA covers angioneurotic edema encounters. The cardiac and cerebrovascular codes (I21–I22, I60–I69) and sepsis codes (A41.9, R65.10–R65.21) reflect HAE's potential for severe systemic complications—use them when those complications are documented, not as a routine attachment.

---